Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial

Clinical Infectious Diseases

Volumn 62, Issue 2, 2016, Pages 173-180

  Davis, Joshua S ^a,b,c   Sud, Archana ^d,e,o   O'Sullivan, Matthew ^f   Robinson, James O ^j,k   Ferguson, Patricia E ^e,g   Foo, Hong ^h   Van Hal, Sebastiaan J ⁱ   Ralph, Anna P ^a,b,j   Howden, Benjamin P ^l,m,n   Binks, Paula M ^a   Kirby, Adrienne ^d   Tong, Steven ^b   Binks, Paula ^b   Majumdar, Suman ^b   Baird, Rob ^b   Gordon, Claire ^b   Jeremiah, Cameron ^b   Leung, Grace ^b   Brischetto, Anna ^b   Crowe, Amy ^b   Dakh, Farshid ^b   Whykes, Kelly ^b   Kirkwood, Maria ^b   Menon, Mahesh ^o   Somerville, Lucy ^o   Subedi, Shrada ^o   Owen, Shirley ^o   Liu, Eunice ^f,j   Zhou, Fei ^f   Robinson, Owen ^g   Coombs, Geoffrey ^g   Ferguson, Patrician ^j   Pollet, Simon ^j   Van Hal, Sebastian ^h,i   Davis, Rebecca ⁱ   more..

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e University of Sydney   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

^g BLACKTOWN HOSPITAL   (Australia)

^h LIVERPOOL HOSPITAL   (Australia)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^j ROYAL PERTH HOSPITAL   (Australia)

^k MURDOCH UNIVERSITY   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m AUSTIN HEALTH   (Australia)

ⁿ MONASH UNIVERSITY   (Australia)

^o NEPEAN HOSPITAL   (Australia)

more..

Author keywords

lactam; bacteremia; clinical trial; MRSA; Staphylococcus aureus; vancomycin;

Indexed keywords

FLUCLOXACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; LIVER TOXICITY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEPTIC SHOCK; ADOLESCENT; ANIMAL; BACTEREMIA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; NEW ZEALAND; PROCEDURES; PROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG THERAPY, COMBINATION; FEMALE; FLOXACILLIN; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NEW ZEALAND; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84960120370     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ808     Document Type: Article

References (29)

1. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71.
2. Turnidge JD, Kotsanas D, Munckhof W, et al. Staphylococcus aureus bacteraemia: A major cause of mortality in Australia and New Zealand. Med J Aust 2009; 191:368-73.
3. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillinsusceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36:53-9.
4. Yaw LK, Robinson JO, Ho KM. A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study. Lancet Infect Dis 2014; 14:967-75.
5. Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev Anti Infect Ther 2007; 5:393-401.
6. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-31.
7. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42(suppl 1):S35-9.
8. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17:990-7.
9. Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731-3.
10. Holmes NE, Tong SY, Davis JS, Hal SJ. Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med 2015; 36:17-30.
11. Davis JS, Hal SV, Tong SY. Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections. Semin Respir Crit Care Med 2015; 36:3-16.
12. Sakoulas G, Okumura CY, Thienphrapa W, et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl) 2014; 92:139-49.
13. Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": taking advantage of the back door left open? Drug Resist Updat 2013; 16:73-9.
14. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J,Walraven C, Mercier RC. Beta-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother 2014; 58:102-9.
15. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. Version 14. Melbourne, Australia: Therapeutic Guidelines, 2010.
16. Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J 2005; 35(suppl 2):S17-24.
17. O'Brien FG, Pearman JW, Gracey M, Riley TV, Grubb WB. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999; 37:2858-62.
18. O'Sullivan MV, Zhou F, Sintchenko V, Gilbert GL. Prospective genotyping of hospital-acquired methicillin-resistant Staphylococcus aureus isolates by use of a novel, highly discriminatory binary typing system. J Clin Microbiol 2012; 50:3513-9.
19. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
20. Wackerly D, Mendenhall W, Schaeaffer R. Mathematical statistics with applications. 7th ed. Duxbury-Thomson Learning, 2008.
21. Nimmo GR, Coombs GW, Pearson JC, et al. Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust 2006; 184:384-8.
22. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158-63.
23. Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014; 36:1317-33.
24. Hoppes T, Prikis M, Segal A. Four cases of nafcillin-associated acute interstitial nephritis in one institution. Nat Clin Pract Nephrol 2007; 3:456-61.
25. Challagundla SR, Knox D, Hawkins A, et al. Renal impairment after high-dose flucloxacillin and single-dose gentamicin prophylaxis in patients undergoing elective hip and knee replacement. Nephrol Dial Transplant 2013; 28:612-9.
26. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496-503.
27. Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: A survey of infectious diseases consultants. Clin Infect Dis 2006; 43:e42-5.
28. Ribera E, Gomez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996; 125:969-74.
29. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713-21.